Arcadia Biosciences
RKDA
25 hedge funds and large institutions have $2.69M invested in Arcadia Biosciences in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 8 closing their positions.
185% more call options, than puts
Call options by funds: $348K | Put options by funds: $122K
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
10% more capital invested
Capital invested by funds: $2.43M → $2.69M (+$255K)
0.05% less ownership
Funds ownership: 0.26% → 0.22% (-0.05%)
7% less funds holding
Funds holding: 27 → 25 (-2)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
+$90.1K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$88.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$56.5K |
| 4 |
State Street
Boston,
Massachusetts
|
+$51.5K |
| 5 |
Jane Street
New York
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$311K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$302K |
| 3 |
MA
MYDA Advisors
Woodmere,
New York
|
-$71.6K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$42K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$36.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
D.E. Shaw & Co
New York
| – | -$22K | -541 | Closed |
|
27
Millennium Management
New York
| – | -$21K | -516 | Closed |
|
|
VF
28
Virtu Financial
New York
| – | -$21K | -515 | Closed |
|
|
EGM
29
Engineers Gate Manager
New York
| – | -$12K | -294 | Closed |
|
|
OLVIG
30
Oliver Lagore Vanvalin Investment Group
Flint,
Michigan
| – | +$143 | +3 | New |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | +$286 | +6 | New |
|
RKDA Hedge Fund Activity: Q1 2022 in Review
25 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q1 2022, worth a combined $2.69M — up 10% from $2.43M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of RKDA and 7 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 7 added.
The largest buyer was Simplex Trading, opening a new position worth an estimated $90.1K. The largest seller was Renaissance Technologies, cutting an estimated $311K.
- 25 institutional investors held Arcadia Biosciences (RKDA) as of Q1 2022, down from 27 in Q4 2021.
- Funds reported $2.69M of Arcadia Biosciences stock for Q1 2022, up 10% quarter-over-quarter.
- 7 funds opened new Arcadia Biosciences positions in Q1 2022 and 8 closed out, a net change of -1 holder.
- The largest Arcadia Biosciences buyer in Q1 2022 was Simplex Trading, an estimated $90.1K added.
- The largest Arcadia Biosciences seller in Q1 2022 was Renaissance Technologies, an estimated $311K sold.
Based on aggregated 13F filings for Q1 2022.